BioTuesdays

Category - Markets

Markets

Maxim starts TFF Pharma at buy; PT $12

Maxim Group launched coverage of TFF Pharmaceuticals (NASDAQ:TFFP) with a “buy” rating and $12 price target. The stock closed at $6.22 on July 7. The company is using its thin film freezing (TFF) platform to develop two...

July 8, 2020
Markets

Chardan starts NGM Biopharmaceuticals at buy; PT $40

Chardan Capital Markets launched coverage of NGM Biopharmaceuticals (NASDAQ:NGM) with a “buy” rating and $40 price target. The stock closed at $19.01 on July 6. “We anticipate that NGM’s aldafermin is likely to...

July 7, 2020
Organigram
Markets

AGP starts Organigram at buy; PT $4

Alliance Global Partners initiated coverage of Organigram Holdings (TSX:OGI) with a “buy” rating and price target of $4 (Canadian). The stock closed at $2.11 on July 6. “We view Organigram’s low-cost indoor [cannabis]...

July 7, 2020
Markets

Chardan starts Akero Therapeutics at buy; PT $79

Chardan Capital Markets launched coverage of Akero Therapeutics (NASDAQ:AKRO) with a “buy” rating and $79 price target. The stock closed at $34.96 on July 6. “We expect that Akero’s lead asset, efruxifermin, has...

July 7, 2020
Venus-Concept-Logo
Markets

BTIG starts Venus Concept at buy; PT $7

BTIG initiated coverage of Venus Concept (NASDAQ:VERO) with a “buy” rating and $7 price target. The stock closed at $3.52 on June 2. “It is not an easy time to be an aesthetics device company amidst the COVID-19...

July 6, 2020
AdaptHealth
Markets

SVB Leerink starts AdaptHealth at OP; PT $21

SVB Leerink launched coverage of AdaptHealth (NASDAQ:AHCO) with an “outperform” rating and $21 price target. The stock closed at $16.10 on June 30. Analyst Stephen Tanal writes that AdaptHealth is fast becoming the...

July 1, 2020
Markets

SVB Leerink starts Applied Molecular at OP; PT $32

SVB Leerink initiated coverage of Applied Molecular Transport (NASDAQ:AMTI) with an “outperform” rating and $32 price target. The stock closed at $25.80 on June 29. “We believe Applied’s emerging translocation...

June 30, 2020
Merus Logo
Markets

HCW starts Merus NV at buy; PT $23

H.C. Wainwright launched coverage of Merus NV (NASDAQ:MRUS) with a “buy” rating and $23 price target. The stock closed at $15.80 on June 25. “Given the recent advances in structure-based design, bispecific antibodies...

June 26, 2020
Mersana Therapeutics Logo
Markets

BTIG ups Mersana Therapeutics PT to $32 from $21

BTIG raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $32 from $21, saying the company’s STING agonist antibody-drug conjugates look compelling on the evolving immunoncology landscape. The stock closed...

June 24, 2020